BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Veltassa (Patiromer) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Veltassa (Patiromer)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06256991-607@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Veltassa (Patiromer): Phase 4 readout est. (NCT06256991)
DESCRIPTION:Veltassa (Patiromer)\, phase 4\, Chronic Kidney Disease.\nStudy
 : Potassium Correction for RAAS Optimization in Chronic Kidney Disease\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/patiromer#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06256991
URL:https://assetmemo.bio/drug/patiromer#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05766839-607@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Veltassa (Patiromer): Phase 2 readout est. (NCT05766839)
DESCRIPTION:Veltassa (Patiromer)\, phase 2.\nStudy: Effect of Patiromer in 
 Children Under 12 Years of Age With High Blood Potassium Levels\nEstimated
  primary completion: 1 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/patiromer#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05766839
URL:https://assetmemo.bio/drug/patiromer#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
